A general outline of the statistical issues in the design and analysis of carcinogenicity bioassays is given in this paper. Design issues, such as assignment of animals to treatment groups, dual control groups, duration of study, and the number of animals per group are discussed. Information needed by the biostatistician are listed to facilitate the recording of data by the pathologist. Issues in the analysis of tumor incidence data are given. Use of historical control data is encouraged and discussed.
group 1, the second animal is assigned to group 2, the third animal is assigned to group 3, and the fourth animal is assigned to group 4. The procedure is repeated with the same systematic arrangement until all the animals are assigned to treatment groups. In the subjective procedure, the animals are assigned to treatment groups by the animal caretaker's whim as the animals are removed from the shipping carton.
The random procedure is the best for preventing bias in an experiment. The subjective procedure is the worst for preventing bias and should never be used. In fact, the subjective procedure usually introduces some bias in the experiment. As a middle ground, the systematic procedure is sometimes used because it is easily implemented for studies with large numbers of animals.
Assignment of Treatment Groups to Cage Position
There are two basic procedures for assignment of treatment groups to cage position: randomized, and systematic. Examples illustrating the procedure are now given for an experiment having four treatment groups. The examples show the treatment group number assigned to a particular cage position at a row and column in the animal rack. In the randomized procedure, a latin square design is randomly chosen from all possible 4 X 4 latin squares. One latin square arrangement for
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1 2 3 4 2 1 4 3 3 4 1 2 4 3 2 1
In the systematic procedure, the treatment groups are assigned to cage positions in a systematic manner. One such arrangement is the following:
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
The random procedure is the best for preventing bias due to cage position. As a middle ground, the systematic procedure is used since dosing errors are less likely with this method.
Control Groups
If dosing is by gavage, then the use of both an environmental and a vehicle control groups is recommended. If dosing is oral via diet or water, then the use of two control groups is at the discretion of the investigator. When good historical control data exists at a location subject to the same set of pathologists and supplier, then perhaps a single control group is sufficient. The advantage of using two control groups is that a measure of the natural biological variability of tumor incidence between groups is obtained. Knowledge of the natural biological variability between groups is helpful in accessing differences between treated and control groups.
Dose Levels
A minimum of three dose levels should be used. The high dose group should be at the "maximum tolerated dose" (MTD). The MTD is determined after careful consideration of all data from dose-ranging studies, metabolism studies, and pharmacokinetic studies. As an example, enzyme-inducing dosages should not be used as the MTD. The mid dose group should be % of the MTD and the low dose group should be % of the MTD.
Duration of Exposure
There are two basic methods for the duration of exposure; fixed, and survival-dependent. In the fixed method, the animals are dosed for a fixed period, usually 24 months, and the study is then terminated. In the survival dependent method, the animals are dosed until survivorship reaches 20% of the original number of animals. Statistically, the fixed method is preferred because the confounding of a real carcinogenic effect with spontaneous lesions common to old age is avoided.
Number of Animals
The statistician, of course, likes to see a large number of animals per group. Practical considerations of housing and laboratory animal husbandry yield to reasonable numbers like 50 to 60 animals per group/sex.
RECORDING OF DATA

Animal Identification Data
For each animal in the study, the following data should be recorded (1): animal ID number, sex, treatment group number, days on study, cage position, and mode of death. The mode of death should be one of the following: scheduled sacrifice, sacrificed in extrernis, or found dead. If the litter of origin is known for the animal, th-en the litter ID number and litter size information should be recorded (1).
Body Weight and Clinical Pathology Data.
For each body weight, clinical chemistry, or hematology value, the animal ID number and observation period should be recorded.
Post Mortem
For each animal in the study, the following data should be recorded: animal ID number, date of sacrifice or death, final body weight, gross observations as per protocol, organ weights as per protocol, and histopathology as per protocol.
Tumor Incidence Data.
For each target organ, all animals will be histologically examined. For each animal, the following data should be recorded: organ or tissue of origin, histological classification e.g., (adenoma/adenocarcinoma), and context of observation e.g., (incidental/fatal). Tumors which directly or indirectly kill their hosts are observed in a fatal context. Tumors which are observed at scheduled sacrifice are observed in an incidental context. Also, tumors observed in an animal which has died of some unrelated cause are observed in an incidental context. If it is difficult for the pathologist to access the context of observation for a particular lesion, a four-point grading system can be arranged in consultation with the biostatistician.
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ANALYSIS ISSUES
Unadjus~ed Analysis
If intercurrent mortality is the same between the treatment groups, then a statistical analysis based on the crude and unadjusted tumor incidences may be used. The unadjusted tumor incidence is simply the number of animals with the lesion divided by the number of animals examined.
Each treated group incidence may be compared with control by use of Fisher's Exact Test (2) or the Chi-square Test (3). A test for linear trend in proportions (dose response test) can be performed by the Cochran-Armitage test (4).
Time-Adjus&ed Ana~ysis
If there are differences in intercurrent mortality, then statistical analysis are used which are based on comparing tumor incidences within time intervals of comparable survival in the study (5 and 6). For fatal tumors, the "death rate" or "life-table" method is appropriate in defining the time intervals. For incidental tumors, the "prevalence" method is appropriate in defining the time intervals.
Historical Controls
The dangers of playing a ''numb~rs" game and ignoring historical control data are becoming evident in the literature. Haseman (7) in a review of patterns of tumor incidence data from 25 NTP studies observed significant intra-and inter-laboratory variability in control data. Clearly, using statistical tests alone and ignoring historical control data can lead to anomalous study conclusions that are not as revelant to risk assessment as they could be.
Pathologists are familiar with using statistical tests based on binomial variation to compare tumor incidence data between treated and control groups. The Cochran-Armtage test is used to detect a linear trend in proportions (dose response). Recently, Tarone (8) has published a statistical method which modifies the Cochran-Armitage test by using historical control incidence data. With good ~~s t o r i c a l control data, Tarone's test may eliminate some of the statistical anomalies currently in the literature because statistical methods that ignore historical control data were used. First of all is survival differences. Obviously if your chemical shortens survival, then you're going to get less tumors in your high dose. The second more subtle factor is body weight differences. As one of the speakers mentioned this morning, mammary tumors in particular tend to go down in incidence as body weight goes down. We were able to demonstrate, in the 25 feeding studies that we looked at, that those studies that had significantly reduced mammary gland fibroadenomas in the Fischer rat invariably had a corresponding decrease in body weight gain. So, that's an example of a factor that can be used often times to explain these decreases. I think that NTP is beginning to pay more attention to the decreases in tumor incidences. If you look at our more recent technical reports, we will even go so far as to say that we feel that some of these are related to the chemical. We're not sure what to make of them. One of the most interesting associations that I'm aware of is one in the Fischer rat. Studies that have an increased incidence of liver tumors tend to have a decreased incidence of leukemia or lymphomas. I guess I'm tossing it back to you to help me to understand why that association should be so. In four or five or six studies (I don't remember that exact number), we found positive liver effects. We found negative leukemia/lymphoma effects. In those 25 studies that we looked at, if you take those out and if you take the mammary gland tumors out and take survival differences out, what you're left with, in the negative trends, is just about what you would expect to see by chance. So, I guess it is my opinion that there are subtle associations. The job is to identify what factors are producing those decreases, then factor that information into account in the interpretation.
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DR. SHOTT: In the latin square dosing scheme there of randomization of the animals, we've always had a concern of the misdosing. That's a very nasty problem, so we have kind of come up with what we consider a type of change in which we take columns and we then randomize the columns across the cage racks and also randomize the cage racks within the room. DR. HAJIAN: Fine. that's okay. I wasn't pontificating. We used to do latin squares. We don't even do that anymore because of the possible mis-dosing problem that could happen. We might go back. The point is: I was just trying to raise everybody's awareness about randomization. . . Also, I didn't answer Dr. Glocklin's question about-why not two high dose groups? I'm trying to measure extra-binomial variability. You want to measure that in your original gene pool. That would be like the environmental control. I'm tying to find out what the distribution of the probability of a certain tumor is for the entire, let's say, CD1 rat population. If I knew that, I could estimate what it would be for the high dose group a little bit easier. I don't mean comparing high dose to control group. I don't mean for that purpose at all I'm not comparing treatment groups. DR. GLOCKLIN: But an environment control and a vehicle control wouldn't necessarily solve that problem. what this questioner over here mentioned. It compares tumor incidence in blocks of time. It compares tumor rates in animals with equivalent survival and then pools that information to get a single overall "P" value. So, by making more use of the survival information in general, it should be better. A case where it can be misleading is a case where the survival differences are so pronounced that there's no overlapping at all. Then you are comparing animals here with no data. There, of course, the test would breakdown and would give you no useful information. What would you do in that situation, I'm not sure. Hopefully, that doesn't happen too often, but I am very surprised. I would say it is a very unusual situation where there are no survival differences and yet the Fisher and the Incidental Tumor Test are so different. I have very rarely seen that happen. I don't know what else to tell you. While I'm up here, let me mention one other comment. Someone mentioned litter effects. I might mention that there are statistical methods for handling data blocked on litter effects. Mantel has written a paper on how to take litter matching into account when you look at tumor incidence. I think that litter can be important, but I think the problem is, at least it has been my experience, we seldom have that level of detail information in the animals we get shipped. We don't normally know if they are litter mates, and we have to sort of assume that the randomization process has more or less randomized out any litter effects. In New Orleans, when this issue came up, I asked someone who had routinely blocked on litter effects and looked at tumor incidence analyses with and without adjusting for litter mates. I asked him if it often makes a difference. His answer was no, that it had the effect of fine tuning the "P" value but. In his experience (he had a lot more than I with litter mates), there weren't that many cases where a littermatched analysis would yield results drastically different from just "crossing your fingers" and hoping that the randomization had more or less randomized that source of variation out.
DR. BALAZS: I'd rather ask than state that the use of a single, inbred, homozygous strain still may not alleviate the need for randomization. Perhaps, it would greatly handicap the detection of cancer-causing potential of the compound when the genetic determinant, either is in the metabolism, or in the reactive ligand formation, like aryl-hydrocarbon hydroxylase. I think this is much less significant than in the genetic determinant, such as the seventeenth chromosome on mice, with the H-2 complex which determines leukemia sensitivity. I think the "allele-locus" is right. Aren't we overlooking things? This is one of the major problems; we are going in circles. It's obvious that it is alright to use dosing the species with the effective dose in the species. I am baffled by the previous speaker, the statisticians's statement that one quarter of the maximum tolerated dose. I was horrified by that figure. That may be a million times the pharmacologic dose.
DR We should have even a data bank, knowing as to which (because the chemical structure obviously is extremely important) of these compounds, but we don't have this type of thing. Yet, theoretically, this is equally important to the opposite. DR. LITT: I'd like to respond to that. The situation at NTP is beautiful. It's ideal in that we have a protocol which has existed for about seven years or more which has been uniform. Set species have been used. The studies have been monitored by contract people. The same laboratories frequently conduct these studies, and the centers that do the analyses are the same.'There are very few industry centers that actually raise their own colony of animals and follow them for long periods of time and provide a historical data base which allows one to make these comparisons. There are also situations in which there are private laboratories which make this information available. But, if we are to draw upon historical data intelligently, we have to follow the sort of lead that NTP is giving us and to use restricted information. The sort of tables which exist in text books, on the subject matter, give you the limits of what is possible but don't really deal in any way with the particular environmental factors which act upon the experiment and which may produce vast changes. It is for this reason that I don't think that it's possible to give an individual company always the kind of information that we would like or the kind of a reaction to a particular set of historical data, which may be random, rather than in the way which has been discussed by two speakers.
DR. BHANDARI: I'd like to pursue thatstatistical significance versus biological significance. I'd like to take a scenario. Say you have a three dose group on a study plus control and you have an incidence in which you have a dose related incidence. The high dose and mid-dose incidence, both are statistically and biologically without arguments. However, in the low dose, the incidence is double than that of the control, although statistically not significant. Now, you cannot, at this point, just say-that's not significant. You do have to take those other two doses where in fact there was statistical significance. I have seen this just because the statistics says; no low dose is noticed, not statistically significant from control. Shouldn't statistics be the one rule accepted rather than the biological analysis which says-no, low dose is also increased in incidence. How do you respond to that? Which one do we accept? DR. HASEMAN: I think you pointed out one of the problems in defining a no-effect level in that what I would intuitively feel was that that was just part of a natural dose/ response model that you had not, because of your restricted number of animals, reached the point of having enough power to call that statistically significant. I would contrast that to the situation where, if I saw the same tumor incidence in the low dose but the middle and the high dose showed no evidence of an effect, I would almost certainly dismiss that as an artifact. I don't think statistically significant or not, one can dismiss a doubling of a backgound rate, particularly if it's lo%, 20%, 30%, 40%. My personal feeling would be that that is not a no-effect level,
